These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 25757683

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.
    Harzstark AL, Small EJ, Weinberg VK, Sun J, Ryan CJ, Lin AM, Fong L, Brocks DR, Rosenberg JE.
    Cancer; 2011 Sep 15; 117(18):4194-200. PubMed ID: 21387258
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Turnbull JD, Cobert J, Jaffe T, Harrison MR, George DJ, Armstrong AJ.
    Clin Genitourin Cancer; 2013 Mar 15; 11(1):45-50. PubMed ID: 23041453
    [Abstract] [Full Text] [Related]

  • 28. Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma.
    Oudard S, Medioni J, Aylllon J, Barrascourt E, Elaidi RT, Balcaceres J, Scotte F.
    Expert Rev Anticancer Ther; 2009 Jun 15; 9(6):705-17. PubMed ID: 19496707
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Rechallenge with mTOR inhibitors in metastatic renal cell carcinoma patients who progressed on previous mTOR inhibitor therapy.
    Maj-Hes A, Medioni J, Scotte F, Schmidinger M, Kramer G, Combe P, Gornadha Y, Elaidi R, Oudard S.
    Oncology; 2013 Jun 15; 85(1):8-13. PubMed ID: 23797151
    [Abstract] [Full Text] [Related]

  • 32. Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far.
    Tang PA, Vickers MM, Heng DY.
    Hematol Oncol Clin North Am; 2011 Aug 15; 25(4):871-91. PubMed ID: 21763972
    [Abstract] [Full Text] [Related]

  • 33. Temsirolimus for advanced renal cell carcinoma.
    Bergmann L, Maute L, Guschmann M.
    Expert Rev Anticancer Ther; 2014 Jan 15; 14(1):9-21. PubMed ID: 24313573
    [Abstract] [Full Text] [Related]

  • 34. [Everolimus (RAD001/Afinitor) in the treatment of metastatic cell carcinoma].
    Gennigens C, Sautois B, Jerusalem G.
    Rev Med Liege; 2010 Apr 15; 65(4):212-6. PubMed ID: 20499824
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. How to interpret phase II data for everolimus plus bevacizumab in renal cell carcinoma.
    Escudier B.
    J Clin Oncol; 2010 May 01; 28(13):2125-6. PubMed ID: 20368540
    [No Abstract] [Full Text] [Related]

  • 39. Therapeutic rationale for mTOR inhibition in advanced renal cell carcinoma.
    Husseinzadeh HD, Garcia JA.
    Curr Clin Pharmacol; 2011 Aug 01; 6(3):214-21. PubMed ID: 21827395
    [Abstract] [Full Text] [Related]

  • 40. Acute cholecystitis in a patient with metastatic renal cell carcinoma treated with everolimus.
    Cetin B, Coskun U, Yildiz R, Buyukberber S, Baykara M, Benekli M.
    J Oncol Pharm Pract; 2011 Sep 01; 17(3):274-8. PubMed ID: 20215482
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.